For More Information:
David McArthur, Senior Manager
502.562.7016 or 502.648.3411
James Graham Brown Cancer Center First in Kentucky to Offer One-Day Treatment
for Early-Stage Breast Cancer
Xoft intraoperative radiation therapy (IORT) offers patients multiple benefits
Louisville, KY. (January 28, 2016) Early-stage breast cancer patients will soon have a new one-day breast cancer treatment option at the James Graham Brown Cancer Center, jointly operated by KentuckyOne Health and the University of Louisville. The cancer center is the first in Kentucky to offer this new technology.
Patients who meet specific selection criteria will be able to be treated with intraoperative radiation therapy (IORT), a one-day breast cancer treatment option that offers multiple patient benefits, including added convenience, fewer treatments and reduced costs.
IORT allows radiation oncologists and breast cancer surgeons to work together to deliver a full, concentrated dose of radiation in one day at the time of lumpectomy, targeting cancer cells and sparing healthy tissue, such as the heart, lungs, and ribs. This compares to traditional breast cancer treatment, which involves daily radiation five days per week, for six to eight weeks. With IORT, radiation is delivered from inside the breast rather than externally, as is done during external beam radiation therapy (EBRT).
“As one of America’s finest cancer treatment and research institutions, our goal is not just to fight cancer, but to win,” said Donald Miller, MD, PhD, director of the James Graham Brown Cancer Center. “The more advanced technology and research available to our multidisciplinary care teams, the more tools we have at our disposal to save lives. IORT is an exciting advancement in breast cancer care.”
“Two major studies have shown IORT is effective, but with fewer side effects than traditional radiation, making it a viable treatment option for appropriate patients,” said Anthony Dragan, MD, radiation oncologist with UofL Physicians and the James Graham Brown Cancer Center. “In addition to fewer side effects, IORT can also help improve access to care. Some women, such as those who live in more rural areas, women who are in the workforce and women who are caretakers for their families, find it difficult to finish a course of traditional treatment that requires multiple visits. Since IORT requires only one dose of radiation, patients are able to return to their normal life within days rather than weeks, a huge improvement over traditional radiation treatment.”
The James Graham Brown Cancer Center will be the first in Kentucky to offer the Xoft® Axxent® Electronic Brachytherapy (eBx®) System®, which is FDA cleared, CE marked and licensed in Canada for the treatment of cancer anywhere in the body, including early-stage breast cancer, gynecological cancers, and nonmelanoma skin cancer.
The Xoft System uses a proprietary miniaturized x-ray source, which is inserted into a flexible balloon-shaped applicator, then temporarily placed inside the lumpectomy cavity. A full course of radiation is then administered in a single dose, lasting as little as eight minutes, which directly targets cancer cells.
“IORT gives patients with early stage breast cancer an integrated surgical and radiotherapy option, in just one treatment, with the hope for the same outcomes,” said Nicolas Ajkay, MD, surgical oncologist with UofL Physicians and the James Graham Brown Cancer Center. “Our multidisciplinary team approach leads to constant collaboration among physicians to find the right treatment plan for each patient. IORT will allow us to do so in new and exciting ways.”
A growing body of favorable clinical data supports the use of IORT in candidates meeting specific selection criteria. iCAD, the maker of Xoft, is currently conducting one of the largest IORT clinical studies to date using the Xoft System, which compares Xoft IORT to traditional external beam radiation therapy. To date, more than 2,000 patients have been treated with Xoft IORT.
For more information about IORT at the James Graham Brown Cancer Center, visit http://www.kentuckyonehealth.org/IORT or call 502.562.HOPE(4673).
About KentuckyOne Health
KentuckyOne Health, the largest and most comprehensive health system in the Commonwealth, has more than 200 locations including, hospitals, physician groups, clinics, primary care centers, specialty institutes and home health agencies in Kentucky and southern Indiana. KentuckyOne Health is dedicated to bringing wellness, healing and hope to all, including the underserved. The system is made up of the former Jewish Hospital & St. Mary’s HealthCare and Saint Joseph Health System, along with the University of Louisville Hospital and James Graham Brown Cancer Center. KentuckyOne Health is proud of and strengthened by its Catholic, Jewish and academic heritages.
About Xoft Axxent Electronic Brachytherapy System
The Xoft System is an isotope-free radiation treatment that is FDA cleared, CE marked, and licensed in Canada for the treatment of cancer anywhere in the body, including treatment of early-stage breast cancer, gynecological cancers and non-melanoma skin cancer. It utilizes a proprietary miniaturized x-ray as the radiation source that delivers precise treatment directly to cancerous areas while sparing healthy tissue and organs. The Xoft System requires only minimal shielding and therefore does not require room redesign or construction investment. Minimal shielding also allows medical personnel to remain in the room with the patient during treatment. The mobility of the Xoft System makes it easy to treat patients at multiple locations and to easily store the system when not in use. Xoft is a wholly owned subsidiary of iCAD, Inc. For more information about Xoft visit www.xoftinc.com, like us on Facebook or follow us on Twitter at @xofticad.
About iCAD, Inc.
iCAD delivers innovative cancer detection and radiation therapy solutions and services that enable clinicians to find and treat cancers earlier and faster while improving patient outcomes. iCAD offers a comprehensive range of upgradeable computer aided detection (CAD) and workflow solutions to support rapid and accurate detection of breast, prostate and colorectal cancers. iCAD’s Xoft® Axxent® Electronic Brachytherapy (eBx®) System® is a painless, non-invasive technology that delivers high dose rate, low energy radiation, which targets cancer while minimizing exposure to surrounding healthy tissue. The Xoft System is FDA cleared, CE marked, and licensed in Canada for the treatment of cancer anywhere in the body, including treatment of early-stage breast cancer, gynecological cancers and non-melanoma skin cancer. The comprehensive iCAD technology platforms include advanced hardware and software as well as management services designed to support cancer detection and radiation therapy treatments. For more information, visit or www.icadmed.com or www.xoftinc.com.